The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | ViPOR regimen for R/R B-cell lymphoma
The Phase Ib study of venetoclax, ibrutinib, prednisone, obinutuzumab and lenalidomide (ViPOR) for relapsed/refractory B-cell lymphoma was presented at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland. Here, Wyndham Wilson, MD, PhD, Center for Cancer Research, National Cancer Institute, Bethesda, MD, explains the safety, efficacy and molecular analysis results.
